Novartis Ag

Sandoz Gmbh

Robert Paul Hof

Roland M Wenger

Sylvain Cottens

Moise Azria

Volker Brinkmann

Gilles Feutren

The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.

Use of S1P receptor agonists in heart diseases

Use for 1,3-propanediol derivatives

Use of a compound of formula (I) wherein R,is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R,, R,, R,and R,, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.

Use of calcium antagonists of formula I ##STR1## wherein the substituents have various significances in the treatment of conditions related directly or indirectly to ionized calcium levels in the blood and combinations of calcium antagonists, e.g. of formula I, with calcitonins.

Growing community of inventors

Gelterkinden, Switzerland

Robert Paul Hof